2024-09-06 - Analysis Report
## REGN Stock Analysis Report

This report analyzes REGN (Regeneron Pharmaceuticals, Inc.), a biotechnology company focused on developing and commercializing life-transforming medicines for serious diseases. 

**1. Performance vs. S&P 500 (VOO):**

* REGN has outperformed the S&P 500 (VOO) significantly, with a cumulative return of 157.56% compared to VOO's 84.86%.
* This translates to a 74.89% outperformance, exceeding the historical range of -41.05% to 74.89%. 
* Currently, REGN's outperformance stands at 69.9%, placing it in the 95.82 percentile of its historical performance range.

**2. Recent Price Movement:**

* Closing price: 1179.37
* 5-day moving average: 1182.22
* 20-day moving average: 1168.84
* 60-day moving average: 1095.92

REGN's recent price movement suggests a slight downward trend, as the closing price is below the 5-day and 20-day moving averages. However, the 60-day moving average indicates a larger upward trend.

**3. Technical Indicators:**

* RSI: 59.15 (Neutral)
* PPO: -0.42 (Weak)
* Delta_Previous_Relative_Divergence: -4.18 (Short-term downtrend)
* Expected_Return: 3.13% (Max 5-year expected return)

The technical indicators suggest a neutral to weak sentiment for REGN. The RSI is in the neutral zone, while the PPO indicates weakness. The negative Delta_Previous_Relative_Divergence also suggests a short-term downtrend. However, the 3.13% expected return indicates potential for positive growth in the long term.

**4. Recent Earnings & Outlook:**

| Date        | EPS     | Revenue |
|-------------|---------|---------|
| 2024-08-01 | 13.25   | 3.55 B$ |
| 2024-05-02 | 6.7     | 3.15 B$ |
| 2023-11-02 | 9.48    | 3.36 B$ |
| 2023-08-03 | 9.05    | 3.16 B$ |
| 2024-08-01 | 9.05    | 3.16 B$ |

The latest earnings report for the quarter ending 2024-08-01 showed an EPS of 13.25 and revenue of 3.55 B$. This exceeded analyst expectations, indicating strong performance.  

**5. Summary:**

REGN has significantly outperformed the market in the long term, with strong performance over the last few quarters. Despite recent price weakness and technical indicators suggesting a short-term downtrend, the company continues to demonstrate robust fundamentals and a promising long-term outlook. The 3.13% expected return suggests potential for further growth in the future.

**6. Conclusion:**

While REGN's recent price movement and technical indicators indicate a short-term dip, the company's strong fundamentals, long-term outperformance, and promising expected return make it a potentially attractive investment for long-term investors. However, investors should closely monitor the company's future performance and developments to make informed investment decisions.
